New trials, publications, preprints and grants on this target, month by month.
Trial
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
1 Dec 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma
1 Jun 2027· PHASE1_PHASE2 · RECRUITING· CTGOV
Trial
Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)
15 May 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)
1 Apr 2027· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
9 Mar 2027· PHASE3 · RECRUITING· CTGOV
Trial
Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer
1 Mar 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE)
31 Jan 2027· NA · NOT_YET_RECRUITING· CTGOV
Trial
HER2 Vaccine for Locally Advanced Breast Cancer
1 Jan 2027· PHASE1 · RECRUITING· CTGOV
Trial
A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer
15 Dec 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer
1 Dec 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV
Trial
Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer
1 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors
30 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
30 Nov 2026· NA · NOT_YET_RECRUITING· CTGOV
Trial
Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer
30 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer
30 Nov 2026· PHASE4 · NOT_YET_RECRUITING· CTGOV
Trial
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
11 Nov 2026· NA · RECRUITING· CTGOV
Publication
Longitudinal PRO-CTCAE assessment in patients with HR+/HER2 - metastatic breast cancer initiating palbociclib: feasibility and symptom trajectories in a multicenter prospective cohort study.
6 Nov 2026· Breast cancer (Tokyo, Japan)· PUBMED
Publication
Treatment outcomes of tucatinib in combination with trastuzumab and pertuzumab as a maintenance therapy for people with HER2+ metastatic breast cancer: a plain language summary of findings from HER2CLIMB-05.
6 Nov 2026· Future oncology (London, England)· PUBMED
Publication
TFAP2A promotes the stemness and metastasis of luminal B/HER2-positive and triple-negative breast cancer cells by enhancing KDM4B transcriptional activity.
5 Nov 2026· Molecular biology reports· PUBMED
Publication
Evolving First-Line Treatment Strategies in ERBB2-Positive Metastatic Breast Cancer: A Review.
5 Nov 2026· JAMA oncology· PUBMED
Publication
Trastuzumab deruxtecan in HER2-expressing urothelial carcinoma: current evidence, biomarker challenges, and future therapeutic strategies.
5 Nov 2026· Expert review of anticancer therapy· PUBMED
Publication
Agreement Between Medical Laboratory Technologists and Pathologists' Assessment of ERBB2 (HER2) Fluorescence In Situ Hybridization Across Breast and Gastric Scoring Criteria.
2 Nov 2026· Applied immunohistochemistry & molecular morphology : AIMM· PUBMED
Trial
Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors
1 Nov 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies
1 Nov 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer
1 Nov 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publication
[Efficacy of sacituzumab govitecan following treatment with trastuzumab deruxtecan in a patient with HR-positive/HER2-low metastatic breast cancer.].
1 Nov 2026· Recenti progressi in medicina· PUBMED
Publication
[CDK4/6 inhibitor to antibody-drug conjugates in HER2-low metastatic breast cancer: sequential therapeutic management of a case report.].
1 Nov 2026· Recenti progressi in medicina· PUBMED